Phase 1b combination study of Tazemetostat with Tecentriq (atezolizumab) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Tazemetostat (Primary) ; Atezolizumab
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Proof of concept
- Sponsors Genentech
- 09 Mar 2017 According to an Epizyme media release, company expects the optimal dose will be established this year.
- 03 Nov 2016 According to an Epizyme media release, status changed from planning to recruiting.
- 22 Jun 2016 According to Epizyme media release, company plans to enroll patients in the second half of 2016.